Revance Therapeutics (RVNC) sunk 20% in premarket trading after it agreed to a revised deal with Crown Laboratories, with the takeover price cut by more than half. Revance (NASDAQ:RVNC) will now ...
Design software “for everyone” is now available in 190 countries, according to the Australian firm’s chief customer officer Rob Giglio. But where’s the product suite headed next, and is it threatened ...
In a report released on December 3, Michael Turrin from Wells Fargo maintained a Buy rating on HubSpot (HUBS – Research Report), with a price target of $750.00. Don't Miss our Black Friday Offers: ...